The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $181.34

Today's change-2.94 -1.60%
Updated April 17 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $181.34

Today's change-2.94 -1.60%
Updated April 17 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc crosses below 125-day moving average

Alexion Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$2.94 or 1.60% to (U.S.)$181.34 and crossing below its 125-day moving average. Shares have lost 0.73% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 9.45% during the last year.

Key company metrics

  • Open(U.S.) $182.00
  • Previous close(U.S.) $184.28
  • High(U.S.) $184.60
  • Low(U.S.) $179.17
  • Bid / Ask-- / --
  • YTD % change-1.99%
  • Volume1,063,661
  • Average volume (10-day)1,015,327
  • Average volume (1-month)1,323,987
  • Average volume (3-month)1,253,964
  • 52-week range(U.S.) $147.30 to (U.S.) $203.30
  • Beta0.65
  • Trailing P/E55.66×
  • P/E 1 year forward30.83×
  • Forward PEG1.25×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.26
Updated April 17 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+29.41%

Based on its net profit margin of 29.41%, Alexion Pharmaceuticals Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.17%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue599555512567
Total other revenue--------
Total revenue599555512567
Gross profit550503473534
Total cost of revenue49524033
Total operating expense396318294357
Selling / general / administrative184158159129
Research & development1259789188
Depreciation / amortization4333
Interest expense (income), net operating--------
Unusual expense (income)33823
Other operating expenses, total--------
Operating income204237219210
Interest income (expense), net non-operating-1-----1
Gain (loss) on sale of assets--------
Other--------
Income before tax205236219212
Income after tax153178166159
Income tax, total52585253
Net income153178166159
Total adjustments to net income--------
Net income before extra. items153178166159
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items153178166159
Inc. avail. to common incl. extra. items153178166159
Diluted net income153178166159
Dilution adjustment--00--
Diluted weighted average shares202201202202
Diluted EPS excluding extraordinary itemsvalue per share0.760.880.830.79
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.880.910.830.80